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Abstract  
 
Bioactive glasses (BG) which contain strontium have the potential to combine the 
known bone regenerative properties of BG with the anabolic and anti-catabolic effects 
of strontium cations. Here we created a BG series (SiO2-P2O5-Na2O-CaO) in which 0 
to 100% of the calcium was substituted by strontium and tested their effects on 
osteoblasts and osteoclasts in vitro. We show that ions released from strontium-
substituted BG enhance metabolic activity in osteoblasts.  They also inhibit osteoclast 
activity by both reducing tartrate resistant acid phosphatase activity and inhibiting 
resorption of calcium phosphate films in a dose-dependent manner. Additionally, 
osteoblasts cultured in contact with BG show increased proliferation and alkaline 
phosphatase activity with increasing strontium substitution, while osteoclasts adopt 
typical resorption morphologies. These results suggest that similarly to the 
osteoporosis drug strontium ranelate, strontium-substituted BG may promote an 
anabolic effect on osteoblasts and an anti-catabolic effect on osteoclasts. These 
effects, when combined with the advantages of BG such as controlled ion release and 
delivery versatility, may make strontium-substituted BG an effective biomaterial 
choice for a range of bone regeneration therapies.    
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1. Introduction 
 
Osteoporosis is common among postmenopausal women and is marked by an 
imbalance in the normal process of bone remodelling. In osteoporotic bone, 
osteoclasts resorb too much bone while osteoblasts fail to create enough, which 
together disrupt the bone microarchitecture leaving it porous and prone to fracture. 
Annual direct costs due to osteoporosis-related fracture in the United States are 
estimated in the range of US$20 billion [1] and its disease burden in Europe is 
estimated to be greater than that attributed to any cancer save lung [2]. Strontium 
ranelate (SrR), sold under the trade name Protelos®, is a drug approved for the 
treatment and prevention of osteoporosis and has been shown to reduce the number of 
hip and vertebral fractures in post-menopausal women [3, 4]. The drug combines two 
atoms of stable strontium with the organic moiety ranelic acid. The cellular mode of 
action of SrR appears to be through the strontium cations themselves, which have 
been shown to work both in vivo and in vitro by stimulating osteoblasts to make new 
bone and preventing osteoclasts from resorbing bone [5, 6]. That is, data suggest that 
SrR works by helping resident cells in the bone to restore the normal bone 
remodelling balance. 
 
Bioactive glasses (BG) form a strong bond with living tissue via the formation of a 
hydroxyapatite layer on their surface [7] and have been used to repair hard tissues in a 
variety of craniofacial, maxillofacial, and periodontal applications [8]. BG particulate, 
for example, is used in a variety of dental procedures [9], and many BG compositions 
can be formed into scaffolds for tissue engineering [10]. Surface reactivity, however, 
is not their only mechanism of action as BG also release ions that promote the 
osteoblast phenotype [11, 12]. In vitro studies have demonstrated that BG stimulate 
osteoprogenitors to differentiate to mature osteoblasts that produce bone-like nodules 
[13, 14]. Similarly, in vivo studies have shown gradual degradation of implanted BG 
with subsequent formation of new bone at the implant surface [15, 16]. Because of 
similarities in their charge and ionic radius, strontium can potentially be substituted 
for calcium in BG, creating a material that may combine the bone bonding and 
osteoblast stimulating properties of BG with the bone anabolic and anti-catabolic 
properties of SrR, and may act as an effective material for bone regeneration 
applications.  
 
Here we created a series of BG (SiO2-P2O5-Na2O-CaO) in which strontium was 
substituted for calcium on a mole percentage basis. We then tested their effects on 
cells cultured both in contact with the BG and treated with culture media containing 
ions released from the BG as they dissolved. The effects of strontium substitution in 
the BG were tested on osteoblast and osteoclast cultures and demonstrate that 
strontium-substituted BG promote osteoblast proliferation and activity and decrease 
osteoclast activity and resorption. As BG are a well-studied biomaterial and excellent 
system for controlled ion release, strontium-substituted BG may find use in a range of 
bone regeneration applications including as porous scaffolds, rigid materials and 
particulate.     
 
2. Materials and Methods 
 
2.1 Bioactive glass synthesis 
 
BG containing 46.46SiO2 – 1.07 P2O5 – 26.38 Na2O – 23.08 (SrO:CaO) (mole %) 
where either no calcium (0%) or 10, 50 or 100% of the calcium was substituted for 
with strontium were produced by a melt-quench route as previously described [17]. 
Briefly, the composition was melted in a platinum crucible at 1400 °C for 90 minutes 
and rapidly quenched in deionised (dH2O) water. BG frits were then ground and 
sieved to yield powders <38 μm in diameter. Some frits were also re-melted at 1450 
°C and poured into pre-heated graphite moulds held just above the glass transition 
temperature (which varied between 450 and 500 °C depending on the percent 
strontium substitution [17]) to obtain rods 10 mm in diameter. Discs 1 mm thick were 
cut from the rods with a low speed diamond saw (Buehler IsoMet®, Dusseldorf, 
Germany) using isopropanol as a coolant. 
 
2.2 Dissolution ion studies 
 
2.2.1 Dissolution ion media 
 
1.5 g/L of BG powder was added to RPMI 1640 or Dulbecco’s modified Eagle’s 
(DMEM) cell culture medium (Invitrogen, Paisley, UK), incubated on a roller at 37 
°C for 4 hours and then passed through a 0.2 μm filter. Samples of dissolution ion 
media were collected after 10, 30, 60, 120, and 240 minutes for elemental analysis. 
Media were supplemented as described in section 2.2.3 and equilibrated in a 37 
°C/5% CO2 incubator overnight before being placed on cells. 
  
2.2.2 Elemental analysis  
 
Cell culture media samples containing dissolution ions from BG were diluted by a 
factor of 10 in dH2O and elemental concentrations of Ca, P, Si and Sr ions were 
measured on an inductively coupled plasma – optical emission spectrometer (ICP-
OES) (iCAP 6000, Thermo Scientific, Waltham, MA, USA).  
 
2.2.3 Cell culture with dissolution ions 
 
The human osteosarcoma cell line, Saos-2, was obtained from the European 
Collection of Cell Cultures (ECACC, Salisbury, UK) and routinely cultured under 
standard conditions (37 °C, 5% CO2/95% air, 100% humidity) in RPMI 1640 media 
supplemented with 10% (v/v) foetal bovine serum (FBS) and 2mM L-glutamine (all 
reagents from Invitrogen). For experiments, cells were plated at 30,000 cells/cm2 and 
cultured for up to 28 days.  
 
The mouse monocyte cell line, RAW264.7, which differentiates to osteoclasts under 
appropriate conditions, was obtained from American Type Culture Collection (ATCC, 
Teddington, UK) and cultured in DMEM containing 4.5 g/L glucose and 1.5 g/L 
sodium bicarbonate (Sigma-Aldrich, Dorset, UK) supplemented with 10% (v/v) FBS 
and 4 mM L-glutamine. The nitrogenous bisphosphonate pamidronate (Sigma), a drug 
known to prevent osteoclast-mediated bone resorption in vivo [18], was added at a 
concentration of 1 μM as a control. For erosion pit studies, an additional control was 
created by adding 1mM SrCl2·6H2O (Sigma) to standard cell culture medium. To 
initiate differentiation, 20 ng/mL soluble murine Receptor Activator for Nuclear 
Factor κ B Ligand (RANKL, PeproTech EC, London, UK) was added. For 
experiments, cells were plated at 30,000/cm2 (unless stated otherwise) and cultured 
for up to 6 days. 
  
2.2.4 Metabolic activity of cells 
 
Cell metabolic activity was measured using the tetrazole MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma), which is reduced to 
formazan by mitochondria in metabolically active cells. 50 μL of a 5 mg/mL solution 
of MTT in phosphate buffered saline (PBS) was added to the culture media of live 
cells at indicated time points. After 2 hours, media was removed and the formazan 
was solubilised in dimethyl sulfoxide.  The absorbance of the resulting solution was 
read on a colorimetric plate reader at 592 nm.  
 
2.2.5 Actin staining of cells 
 
Differentiated RAW264.7 cultures were fixed for 15 minutes in 4% (w/v) 
paraformaldehyde in dH2O.  After fixation, cultures were washed in PBS, 
permeabilised in 1% (v/v) Triton X-100 in dH2O for 5 minutes, washed again and 
then stained for 20 minutes with AlexaFluor 568 Phalloidin (Invitrogen; 5 U/mL in 
1% (w/v) bovine serum albumin (BSA) in PBS) to visualise the actin cytoskeleton. 
Cultures were then rinsed with 1% (w/v) BSA in PBS and DAPI was added to stain 
cell nuclei.  Cultures were then imaged using an epifluorescent microscope.  
 
2.2.6 Tartrate resistant acid phosphatase (TRAP) activity and total cell 
quantification 
 TRAP activity, a marker of osteoclast differentiation and resobing activity [19], was 
measured in RAW264.7 cells by quantifying the conversion of p-nitrophenyl 
phosphate to p-nitrophenyl in the presence of sodium tartrate under acidic conditions. 
After 2, 4, or 6 days in culture, cells were lysed in dH2O by three freeze-thaw cycles 
and 1 mg/mL p-nitrophenyl phosphate in 0.1 M glycine buffer with 0.1 mM ZnCl2, 
0.1 mM MgCl2 and 20 mM sodium tartrate (pH = 5.0) was added to the lysates. The 
reaction was stopped with 1 M NaOH and the absorbance read at 405 nm on a 
colorimetric plate reader. TRAP activity is expressed as nmoles p-nitrophenyl 
liberated per minute. The total number of cells in the same lysates was determined by 
quantifying the activity of the stable cytosolic enzyme lactate dehydrogenase with a 
Cytotox96® Non-Radioactive Cytotoxicity Assay (Promega, Southampton, UK), 
according to the manufacturer’s instructions.  
 
2.2.7 Erosion pit formation by osteoclasts 
 
The formation of erosion pits by differentiated RAW264.7 cells was evaluated using 
BioCoatTM OsteologicTM (BD Biosciences Europe, Erembodegem, Belgium) chamber 
well slides which are coated with a thin calcium phosphate (CaP) layer suitable for 
cell culture. 9600 cells/well were cultured for 4 days in the presence of 20 ng/mL 
RANKL with either no additional supplements, 1 mM SrCl2·6H2O, 1 μM 
pamidronate, or BG dissolution ion media. Cells were removed with sodium 
hypochlorite and slides stained with silver nitrate according to the manufacturer’s 
instructions. Micrographs of stained wells were taken on an inverted light microscope 
and the eroded area was determined using the histogram function in ImageJ (freeware 
from the NIH).   
 
2.3 Bioactive glass discs studies 
 
2.3.1 Cell culture on bioactive glass discs 
  
BG discs were sterilised under UV light for 2 hours per side and preconditioned for 
three days in RPMI 1640 medium (exchanged every day). 30,000 Saos-2 cells/cm2 
were seeded on BG discs and cultured for 1, 7, or 14 days in standard culture medium, 
which was exchanged three times per week. 50,000 RAW264.7 mouse 
monocytes/cm2 were also seeded on 0% strontium BG discs and differentiated for 4 
days in standard medium supplemented with 50 ng/mL RANKL to visualise 
osteoclast differentiation. 
 
2.3.2 Scanning electron microscopy (SEM) of osteoclasts 
 
After 4 days, RAW264.7 cells on 0% BG discs were prepared for SEM imaging to 
view osteoclasts. Discs were washed twice in PBS and fixed in 2.5% (v/v) 
glutaraldehyde in 0.1M sodium cacodylate buffer (pH 7.3) for 40 minutes at 4 °C. 
Samples were then washed twice in PBS and dehydrated in a graded ethanol series 
followed by critical point drying with hexamethylsilasane. Following fixation, discs 
were sputter coated with gold and viewed on a Leo 1525 Gemini SEM operated at 10 
kV.  
 
2.3.3 Alkaline phosphatase (ALP) activity and total cell quantification 
 
ALP activity, a marker of osteoblast differentiation and mineralisation, was measured 
in Saos-2 cultured on BG discs using the substrate p-nitrophenyl phosphate. At 
indicated time points, cultures were lysed in dH2O containing 0.9% (v/v) Triton X-
100 and reacted with 1 mg/mL p-nitrophenyl phosphate in 0.1 M glycine buffer with 
0.1 mM ZnCl2 and 0.1 mM MgCl2 (pH = 10.4). The reaction was stopped with 1 M 
NaOH and the absorbance read on a colorimetric plate reader at 405 nm. The total 
number of cells in the same lysates was determined using a Cytotox96® Non-
Radioactive Cytotoxicity Assay according to the manufacturer’s instructions. 
 
2.4 Statistical analyses 
 
Statistical significance in MTT, TRAP and ALP assays was assessed by ANOVA 
with post-hoc LSD test to determine statistical significance between individual 
groups. A two-tailed Spearman’s rho rank correlation was used to determine statistical 
significance in erosion pit area experiments. A p value of les s than 0.05 was 
considered statistically significant. For experiments on BG discs, n = 6 per 
composition per time point. Erosion pit area data represent means of 2 experiments 
and average data from at least 4 wells.  
 
3. Results 
 
3.1 Bioactive glass formation 
 
BG frits and rods were optically clear and were shown to be amorphous by X-ray 
diffraction [17]. Solid state nuclear magnetic resonance and vibrational spectroscopy 
further demonstrated that 0, 50 and 100% substituted BG had predominantly Q2 
silicate structures [17].   
 
3.2 Dissolution ions studies 
 
3.2.1 Ion release 
 
The elemental concentrations of Ca, P, Si and Sr released from BG into cell culture 
media are shown in Figure 1. The dissolution of calcium into both RPMI 1640 and 
DMEM was dependent on BG composition, with decreasing media calcium 
concentration with increasing strontium substitution. The phosphorus concentration in 
RPMI 1640 changed little over the 4 hour release period while in DMEM a general 
decrease in phosphorus concentration was observed for all BG compositions. The 
concentration of silicon in both RPMI and DMEM increased with dissolution time 
and was variable depending on culture media type and BG composition. The 
concentration of strontium was dependent on BG composition with increasing 
strontium substitution resulting in higher media strontium concentrations after 4 
hours.  
 
3.2.2 Metabolic activity of cells 
 
After 1 and 7 days in culture, there were no significant differences in the MTT 
activity of Saos-2 cells treated with BG dissolution ions compared to cells in standard 
culture medium (Figure 2). After 14 and 28 days in culture, the MTT activity in cells 
treated with dissolution ions from all compositions of BG was significantly enhanced 
compared to controls. After 14 days in culture, MTT activity was significantly greater 
in Saos-2 cells treated with dissolution ions from 10, 50 and 100% substituted BG 
compared to 0% substituted BG. After 28 days in culture, cells treated with 
dissolution ions from 100% strontium-substituted BG had significantly higher MTT 
activity than that in any other group.  
 
3.2.3 Formation of erosion pits by osteoclasts 
 
RAW264.7 cells treated with RANKL formed erosion pits on CaP-coated slides 
(Figure 3a) while those treated with RANKL and 1 μM pamidronate formed very few 
erosion pits (Figure 3b). Mean erosion pit area, an indicator of osteoclast activity, 
decreased when RAW264.7 monocytes were treated with dissolution ions from BG in 
which an increasing proportion of calcium was substituted for with strontium (Figure 
3c). The correlation coefficient between strontium substitution and mean erosion pit 
area was r2 = 0.94, which was statistically significant by Spearman’s rho rank 
correlation.  
 
3.2.4 Osteoclast differentiation and TRAP activity 
 
RAW264.7 cells differentiated to large multinucleated osteoclasts in the presence of 
RANKL. Actin staining highlighted typical podosome belts in mature osteoclasts 
which appeared as prominent rings encasing multiple nuclei (Figure 4a). Cultures 
treated with RANKL and 1 μM pamidronate (Figure 4b) failed to form osteoclasts 
with distinctive podosome belts. After 4 days in culture, cells treated with dissolution 
ions from 100% strontium-substituted BG showed significantly less TRAP activity 
when compared to all other BG treated groups (Figure 4c).  After 6 days in culture, 
RAW264.7 treated with dissolution ions from 10%, 50% and 100% strontium-
substituted BG all had significantly lower TRAP activity when compared to cells 
treated with dissolution ions from 0% BG. The presence of 1 μM pamidronate 
significantly reduced total TRAP activity at all time points compared to all other 
groups. The presence of dissolution ions from all BG compositions, however, did not 
have an effect on cell number as no significant differences were detected between any 
groups at any time point (Figure 4d). When TRAP activity was normalised to cell 
number, similar trends were noted although ANOVA determined them not be 
significant with the exception that the group treated with 1 μM pamidronate had 
significantly lower TRAP activity per cell than any other group at any time point 
(Supplementary Figure 1).  
 
3.3 Bioactive glass discs studies 
 
3.3.1 Total cell quantification  
 
The total number of Saos-2 cells on BG discs increased over the two week culture 
period for all BG compositions (Figure 5a). After 24 hours in culture, there were no 
significant differences between the number of cells on any BG disc composition. 
However, after 7 days in culture, there were significantly more cells on 100% 
substituted BG discs than on 0%, and after 14 days in culture, there were significantly 
more cells on 50 and 100% strontium-substituted BG discs compared to either 0 or 
10% strontium-substituted BG discs.  
 
3.3.2 ALP activity 
 
Saos-2 cells cultured on BG discs showed increased total ALP activity with increasing 
strontium substitution for calcium (Figure 5b). There were no significant differences 
in total ALP per disc after 24 hours in culture, but after 1 week, cells on 100% 
strontium-substituted BG discs had significantly higher total ALP activity than those 
on 0% or 10% BG discs. After 2 weeks in culture, cells on BG discs with 50 or 100% 
strontium substitution had significantly higher total ALP activity than those on discs 
with 0% or 10% strontium substitution. This trend held when ALP activity was 
normalised per cell number as determined by LDH activity.  There were no significant 
differences after 1 or 7 days in culture, but after 2 weeks, cells on BG discs containing 
50 and 100% strontium substitution had significantly higher ALP activity per cell than 
those on 0% strontium-substituted BG discs (Supplementary Figure 2).  
 
3.3.3 SEM of osteoclasts 
 
RAW264.7 monocytes cultured on standard BG discs differentiated to large cells with 
apico-basal polarisation, morphology typical of resorbing osteoclasts (Figure 6).  
Osteoclasts with similar morphologies were observed adherent to the surfaces of all 
BG compositions by SEM (not shown). Many undifferentiated monocytes were also 
visible.  
 
4. Discussion 
 
Calcium has been reported to act as a network modifier in BG. As strontium has a 
similar charge and ionic radius to calcium, when it is substituted into the glass 
network, it may play a similar role. The lower charge to size ratio of the strontium ion 
compared to the calcium ion (due to the slighter larger ionic radius of strontium), 
however, should create an expanded and more loosely cross-linked glass network, but 
not fundamentally alter the glass structure.  
 
The release of Ca, P, Si and Sr into cell culture medium during incubation with BG is 
complicated by ions already present in cell culture media, which themselves vary 
among media formulations. Our ICP-OES data show that despite its release from the 
BG, the calcium concentration in RPMI 1640 decreases and in DMEM stays fairly 
constant with incubation time. This is likely due to the formation of a CaP layer on 
the surface of the BG particles during incubation, which depletes the culture media of 
calcium [20]. This hypothesis is supported by the decrease in phosphorus 
concentration over time during incubation of BG in DMEM. The high concentration 
of phosphorus in RPMI 1640 (174 ppm) provides an excess available to form the CaP 
layer and so its concentration does not significantly diminish during incubation.  
 
Silicon, which is thought to be responsible for the cell-stimulating activities of BG 
dissolution ions due its essential role in bone formation [21] is released into culture 
media over time due to the breakup of the outer silica layers of the BG network [10]. 
While silicon release into simulated body fluid is reported to happen quickly (30 
minutes to 2 hours), release into cell culture media proceeds more slowly [20], and 
although our data show that the silicon concentration in cell culture media increases 
with time for all BG compositions and in both media formulations, it does not reach 
its solubility limit. As expected, the substitution of strontium for calcium in BG 
results in increased levels of strontium in both RPMI 1640 and DMEM cell culture 
media. Taken together, these data suggest that the glass chemistry can be tailored to 
release an appropriate level of strontium and/or other ions depending on the 
application.   
 
At early time points, the metabolic activity of Saos-2 cells treated with BG dissolution 
ions was not significantly different from that observed in cells treated with standard 
culture medium indicating that the dissolution products of all compositions of BG 
were non-cytotoxic. However, after 2 weeks in culture, dissolution ions from all 
formulations of BG enhanced total metabolic activity in Saos-2 cells compared 
controls. This has been previously shown in primary human osteoblasts treated with 
45S5 Bioglass® dissolved in DMEM, which showed increased proliferation 
compared to controls [22]. We also noted that MTT activity in cells treated with 
strontium-substituted BG was significantly enhanced compared to non-strontium-
containing groups. This suggests that dissolution ions released from the strontium-
substituted BG further enhance metabolic activity in Saos-2 beyond that caused by the 
presence of dissolution ions from standard BG. This is in agreement with previous 
studies which have shown that SrR promotes osteoblast proliferation [23] and 
suggests that strontium ions may act synergistically with other ions (most likely 
silicon) released from BG. 
 
Treating RAW264.7 monocytes with dissolution ions from BG with increasing 
strontium substitution reduced erosion pit area on CaP-coated glass slides. This 
suggests that the strontium ions either inhibit osteoclast differentiation or prevent 
mature osteoclasts from eroding the coating. SrR has been previously shown to both 
inhibit osteoclast differentiation and resorption activities in vitro [24]. Recent studies 
have suggested that modulation of osteoprotegerin and RANKL expression, known 
regulators of osteoclast activity and resorption, are responsible for this effect [25]. 
Others, however, have shown that SrR inhibits osteoclast activity by preventing the 
formation of the ruffled border region and clear zone necessary for sealing and 
erosion pit formation [5, 26]. Our data show that dissolution ions from strontium-
containing BG did not prevent erosion pit formation to the same extent as the 
bisphosphonate pamidronate. Bisphosphonates act by disrupting the mevalonate 
pathway, disturbing osteoclast cytoskeleton formation and their ability to form a 
ruffled border region (reviewed in [27]). The mechanism by which strontium ions 
prevent erosion pit formation in the present study is not clear, but inhibition of 
differentiation and disruption of cytoskeletal elements are two possibilities.  
 
Substituting strontium for calcium in BG significantly decreased TRAP activity in 
cultures treated with their dissolution ions. ICP-OES demonstrated that DMEM cell 
culture medium treated with 100%-substituted BG had a strontium concentration of 
84 ppm which is similar to the concentration of strontium in cultures supplemented 
with 1mM Sr2+ (88 ppm) (as either SrCl2·6H2O or SrR), which has also been shown to 
prevent osteoclast-mediated erosion of dentine slices [26] and apatite-coated matrices 
[5]. This level, however, is still higher than that in the serum of patients treated with 
SrR (0.12 mM Sr2+ or ~10 ppm [3]). Decreased TRAP activity, however, did not 
come as a result of cell death. While there is evidence of an apoptotic effect of SrR on 
osteoclasts [28, 29], we could not detect significant differences in the number of cells 
in different groups at any time point. This is in agreement with studies which have 
shown that SrR does not affect attachment to or viability of osteoclasts on bone slices, 
but does reduce osteoclast differentiation and resorption activity [24]. Hurtel-Lemaire, 
et al. have shown that SrR does induce osteoclast apoptosis, however, this was only 
evident at Sr2+ concentrations of 9 mM and higher, far more than that tested here and 
more than order of magnitude higher than that present in the serum of patients treated 
with SrR [29]. 
 
No addition of strontium to cell culture media by dissolution ions from BG reduced 
TRAP activity to the same extent as pamidronate. This is in keeping with results from 
a recent clinical trial that demonstrated a more subtle bone remodelling effect of SrR 
as compared to other osteoporosis treatments [30]. Parathyroid hormone (PTH) 
treatment enhances bone mineral density by both increasing bone formation and 
resorption. Anti-catabolic agents such as bisphosphonates, on the other hand, inhibit 
bone turnover, preserving the existing skeletal microarchitecture. Because of its mode 
of action, there has been concern that long-term treatment with bisphosphonates may 
‘freeze’ bone, prohibiting normal repair processes. Recent reports of osteonecrosis in 
the jaw of patients treated with bisphosphonates seem to confirm this [31]. Neither 
PTH nor bisphosphonate treatments, however, address the lost bone remodelling 
balance inherent to osteoporosis. Bone regeneration therapies involving strontium 
may be preferred in this regard as they prevent osteoclast resorption without 
diminishing bone mineralisation and formation.  
 
Strontium-substituted BG not only stimulated increased osteoblast metabolic activity 
and inhibited osteoclast differentiation and resorption via their dissolution ions, but 
also promoted osteoblast proliferation and ALP activity while directly in contact with 
cells. This is in agreement with studies on standard BG which have been shown to 
stimulate the expression of a number of osteogenic genes (reviewed in [32]), although 
the mechanism by which ions released from BG act on cells remains unclear. There is 
evidence that strontium’s effect is mediated by cation-sensing receptors other than the 
calcium-sensing receptor (CaSR) [33, 34]. This is supported by data demonstrating 
that neither calcium nor sodium ranelate had the same effects as their strontium 
counterpart [23, 26]. However, this  has been refuted by other studies which have 
demonstrated that strontium’s effect is CaSR dependent [25, 29], although an effect 
mediated by a combination of receptors cannot be ruled out.  
 
Osteoclasts on BG discs assumed typical resorption morphologies, which was in 
contrast to non-resorbing morphologies noted in osteoclasts on tissue culture plastic. 
Previous studies have demonstrated that only when adherent to apatite do osteoclasts 
assume typical apico-basal polarisation and form sealing rings [35] suggesting that the 
BG discs examined in this study are sufficient to elicit a normal bone remodelling 
response. Our data also suggest that ions dissolved from BG are not sufficient on their 
own to promote a resorption phenotype as osteoclasts cultured on tissue culture plastic 
in the presence of BG dissolution ions maintained flattened non-resorbing 
morphologies. This is in agreement with previous studies which have shown that 
microenvironmental cues alone do not trigger osteoclast polarisation and sealing zone 
formation [35]. 
 
5. Conclusions 
 
Strontium can be substituted for calcium in BG, creating a biomaterial that increases 
osteoblast proliferation and ALP activity, and inhibits TRAP activity and osteoclast-
mediated resorption of CaP films, similarly to the osteoporosis drug SrR. As BG are a 
well-studied biomaterial system capable of controlled ion release and are deliverable 
as particulate, scaffolds or bulk material, substitution of strontium for calcium in BG 
may be an effective strategy for creating materials for bone repair/regeneration 
therapies. 
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Figure captions 
 
Figure 1: Elemental concentrations of Ca, P, Si and Sr as determined by ICP-OES in cell culture media over 4 
hours incubation with BG particles in which 0, 10, 50 or 100% of the calcium was substituted for with strontium. 
Dissolution behaviour into a. RPMI 1640 and b. DMEM. 
 
Figure 2: Normalised MTT activity of Saos-2 human osteosarcoma cells treated with dissolution ions from 
standard BG and BG in which increasing proportions of calcium were substituted for with strontium. Data 
represent mean + standard deviation and are normalised to the mean value of controls after 1 day in culture. * 
indicates significantly higher MTT activity in the indicated group compared to the control group at the same time 
point. † compared to 0%, ‡ compared to 10%, and § compared to 50% (all at the same time point). 
 
Figure 3: Representative images of erosion pits (bright) formed on calcium phosphate-coated chamber slides by 
RAW264.7 mouse monocytes cultured for 4 days in the presence of either a. RANKL alone or b. RANKL 
combined with 1 μM pamidronate, a drug known to prevent osteoclast-mediated bone resorption in vivo. Scale 
bar in a and b is 1 mm. c. Mean erosion pit area (± standard deviation) in calcium phosphate-coated chamber 
slides formed by RAW264.7 cells treated with RANKL and culture media containing dissolution ions from 
standard and strontium-substituted BG (■).  Cultures supplemented with RANKL alone (CNT ○), 1 μM 
pamidronate (PAM ○) and 1 mM SrCl2 (▲) are shown as controls.   
 
Figure 4: a. Representative epifluorescense micrograph showing large multinucleated osteoclasts with typical 
podosome belts (arrows) in cultures of RAW264.7 mouse monocytes after 4 days treatment with RANKL and 
dissolution ions from 50% strontium-substituted BG. b. Epifluorescense micrograph of RAW264.7 treated with 
RANKL and 1 μM pamidronate in which no multinucleated osteoclasts are visible. Red = phalloidin (actin), Blue = 
DAPI (nuclei). Scale bar in a and b is 200 μm. c. Total TRAP activity (mean + standard deviation) expressed as 
nmoles p-nitrophenyl liberated per minute in the presence of 20 mM tartrate in RAW264.7 differentiated in BG 
dissolution ion media or with 1μM pamidronate. All cultures were supplemented with 20 ng/mL RANKL. 
Pamidronate significantly reduced total TRAP activity at all time points compared to all other groups (#). After 4 
days, RAW264.7 treated with 100% strontium-substituted BG had significantly reduced TRAP activity compared 
to all other glass treated groups and CNT (*compared to CNT at same time point; † compared to 0%; ‡10%; 
§50%). After 6 days, cells treated with 10, 50 and 100% strontium-substituted BG had significantly lower TRAP 
activity when compared to 0% (†). d. Total number of cells in cultures of RAW264.7 monocytes treated with 
dissolution ions from BG or pamidronate. There were no significant differences between the number of cells 
detected in any group. 
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Figure 5: a. Total number of cells on BG discs after 1, 7 and 14 days in culture as determined by measuring 
lactate dehydrogenase activity. After 7 days in culture, there were significantly more cells on 100% substituted 
BG discs than on 0%, and after 14 days in culture there were significantly more cells on 50 and 100% strontium-
substituted BG discs compared to either 0 or 10% († significantly more cells compared to 0% at the same time 
point, ‡ compared to 10%).  b. Total alkaline phosphatase (ALP) activity (mean + standard deviation) in Saos-2 
cells on 0% strontium BG discs and BG in which 10, 50 or 100% of the calcium was substituted for with 
strontium. After 7 days in culture, cells on 100% strontium-substituted BG discs had significantly higher total ALP 
activity than those on 0% or 10% substituted BG discs. After 2 weeks in culture, cells on discs in which 50 or 
100% of the calcium had been substituted for with strontium had significantly higher total ALP activity than those 
on 0% or 10% strontium-substituted BG discs († significantly greater total ALP activity compared to 0% at the 
same time point, ‡ compared to 10%).  
  
Figure 6: SEM image of osteoclast on 0% strontium-substituted BG disc after 4 days in culture. A large 
osteoclast with a typical apico-basal polarised resorbing morphology (black arrow) is visible as are many 
undifferentiated monocytes (white arrows). Scale bar is 100 μm.  
 
Supplementary Figure 1: Tartrate resistant acid phosphatase (TRAP) activity normalised to cell number in 
RAW264.7 monocytes differentiated for 2, 4 and 6 days in media containing dissolution ions from BG or 1μM 
pamidronate. All cultures were supplemented with RANKL. Pamidronate significantly reduced TRAP activity per 
cell (* ). Although TRAP activity per cell decreased when cells were treated with dissolution ions made from BG 
with increasing strontium substitution for calcium, this trend was not significant.  
 
Supplementary Figure 2: Alkaline phosphatase (ALP) activity normalised to cell number of Saos-2 human 
osteosarcoma cells on discs of standard BG and BG in which 10, 50 or 100% of the calcium was substituted for 
with strontium. After 14 days in culture, cells on 50 and 100% substituted BG had significantly higher ALP activity 
per cell than cells on 0% substituted BG. 
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